Last updated: February 16, 2026
Product Overview
NDC 00641-6135 refers to Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor used in the treatment of multiple cancers, including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, and others. Approved by the FDA for several indications, Nivolumab has established a significant position within oncology treatments.
Market Size and Demand Drivers
The total global oncology drug market exceeds $150 billion annually. Nivolumab accounts for a sizable share, with estimated U.S. sales surpassing $4 billion in 2022. The growing prevalence of targeted cancers and improved survival rates contribute to sustained demand.
Key factors influencing market demand:
- Expanding indications: FDA approvals for additional cancer types augment patient base.
- Combination therapies: Combining Nivolumab with other agents increases treatment options.
- Competitive landscape: Key rivals include Pembrolizumab (Keytruda) and Atezolizumab (Tecentriq).
- Pricing strategies: Premium pricing maintained due to clinical efficacy and limited biosimilar competition.
Competitive Positioning
| Drug |
Indications |
Estimated 2022 U.S. Sales |
Patent Status |
Biosimilar Presence |
| Nivolumab |
Multiple cancers, approved 2015 |
~$4.2 billion |
Patent until 2028 |
No biosimilars approved near-term |
| Pembrolizumab |
Similar indications, 2014 |
~$6.5 billion |
Patent until 2030 |
Biosimilars in early development |
| Atezolizumab |
Similar indications |
~$1.4 billion |
Patent until 2027 |
No biosimilars available |
Pricing Dynamics
Average wholesale price (AWP) per 100 mg dose is approximately $10,000. The cost varies by indication, line of therapy, and payer negotiations. Net prices after discounts and rebates are typically 15-20% lower.
Current list price for a standard 240 mg dose (administered every 2 or 3 weeks) is roughly $24,000.
Price Projections (Next 5 Years)
| Year |
Estimated Average Price per 100 mg |
Factors Influencing Price Changes |
| 2023 |
~$10,000 |
Stable pricing; patent protections intact |
| 2024-2025 |
$9,500 - $10,000 |
Slight discounts due to increased market competition |
| 2026-2027 |
$9,000 - $9,500 |
Biosimilar entry possible; negotiations pressure on list prices |
| 2028-2029 |
About $8,500 - $9,000 |
Patent expiry; biosimilar market penetration |
| 2030 |
~$8,000 |
Increased biosimilar availability reduces brand price |
Market Risks and Opportunities
Risks:
- Patent expiration: Biosimilars anticipated to enter U.S. and European markets post-2028.
- Pricing pressure: Payer negotiations and value-based pricing models may lower net prices.
- Competitive approvals: New immunotherapies and combination regimens could erode market share.
Opportunities:
- Expansion into new indications: Regulatory approval for earlier-stage cancers broadens the user base.
- Combination therapies: Clinical studies combining Nivolumab with other agents may enhance efficacy and justify premium pricing.
- Specialty pharma partnerships: Collaborations to improve access and develop biosimilars or generics.
Regulatory and Reimbursement Environment
U.S. regulatory status supports broad use across multiple approvals since 2015. CMS and private payers increasingly favor value-based care, which may impact reimbursement rates.
In Europe, Nivolumab faces similar market conditions but with regional pricing controls. As biosimilars gain approval, European prices are expected to decline by 20-30% over the next five years.
Summary
Nivolumab (NDC 00641-6135) remains a high-value oncology asset with stable demand and premium pricing driven by clinical benefit and limited biosimilar competition in the near-term. Price reductions are anticipated post-2028 amid biosimilar entry, with potential growth opportunities in expanding indications and combination therapies.
Key Takeaways
- Nivolumab's revenue reached over $4 billion in 2022 in the U.S.
- List prices hover around $10,000 per 100 mg dose, expected to decline gradually.
- Patent expiry after 2028 and biosimilar entry will pressure prices.
- Increasing indications and combination regimens sustain market demand.
- Market risks include competition from biosimilars and emerging therapies; opportunities lie in expanding uses and partnership strategies.
FAQs
1. When do biosimilars for Nivolumab become available?
Biosimilar applications are progressing through regulatory pathways. European approvals could occur around 2025-2026; U.S. biosimilar approvals are likely shortly thereafter, around 2028.
2. How does Nivolumab’s pricing compare with competitors?
Pricing is similar to Pembrolizumab, slightly lower than it in terms of list price per mg but generally on par due to comparable efficacy across indications.
3. Which indications drive the highest revenue for Nivolumab?
Non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma generate the majority of sales, accounting for over 70% of revenue.
4. What factors could accelerate market penetration of biosimilars?
Regulatory approvals, accelerated biosimilar acceptance in payers, and price discounts contribute to faster adoption.
5. What is the potential impact of combination therapies on Nivolumab’s market share?
Combination regimens, such as Nivolumab with Ipilimumab, may extend the market share and increase treatment efficacy, supporting premium pricing and growth.
Citations
- IQVIA, 2022 Data.
- FDA.gov, Nivolumab Approvals.
- EvaluatePharma, Oncology Market Trends.
- CNBC, Oncology Drug Pricing.
- Biosimilar Development Updates, 2022.
